This randomized, crossover clinical trial evaluated the efficacy and safety of tadalafil compared with darifenacin in managing lower urinary tract symptoms (LUTS) and pain related to indwelling ureteric stents. A total of 150 patients who underwent ureteric stent insertion after endoscopic treatment of ureteric stones were enrolled. Patients were randomized into two groups: Group 1 received tadalafil 5 mg once daily for 3 weeks, followed by a 1-week washout, then darifenacin 7.5 mg once daily for 3 weeks. Group 2 received the reverse sequence.

The primary outcome was change in LUTS as measured by a shortened International Prostate Symptom Score (IPSS). The secondary outcome was stent-related pain measured by the Numeric Pain Rating Scale (NPRS). Drug safety and tolerability were also assessed.

Inclusion Criteria:

1. Age:18-40 years
2. Patient with ureteric stent size 6 Fr-26 cm post endoscopic procedure.

Exclusion Criteria:

1. Known prostatic patient with LUTS
2. Pregnant or lactating women
3. Recurrent urinary tract infection.
4. Neurological diseases.

The datasets generated and analyzed during the current study will not be publicly available due to institutional restrictions, but are available from the corresponding author on reasonable request.